Emerging Targets in Anti-Tubercular Drug Design

Keith D. Green, Selina Y.L. Holbrook, Huy X. Ngo, Sylvie Garneau-Tsodikova

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

2 Scopus citations


Tuberculosis (TB) is currently the second most lethal infection following HIV. In 2014 alone, there were 9.6 million new cases of TB and 1.5 million TB-related deaths reported worldwide. It is also estimated that about one third of the entire population carries latent Mycobacterium tuberculosis (Mtb), the etiological cause of TB. These individuals are asymptomatic, but can develop a full TB infection if left untreated. The current first-line TB treatment consists of a cocktail of isoniazid, rifampicin, pyrazinamide, and ethambutol. A fraction of Mtb strains develop resistance to isoniazid and rifampicin and are usually treated with second-line anti-tubercular agents, such as aminoglycosides, fluoroquinolones, or the antimicrobial peptide capreomycin. Some strains acquire further resistance to second-line treatments, causing a significantly higher mortality rate. The increase of drug-resistant Mtb strains has triggered action in the scientific field, which has led to a renaissance in anti-tubercular drug discovery with multiple emerging drug targets. Herein, we summarize the latest enzymes, pathways, and mechanisms presented in the literature (covering 2000-2016) related to the emergence of promising targets in anti-tubercular drug design.

Original languageEnglish
Title of host publicationAllosterism in Drug Discovery
EditorsDavid Thurston, Troy Lister, Steven M. Firestine
Number of pages63
StatePublished - 2017

Publication series

NameRSC Drug Discovery Series
ISSN (Print)2041-3203
ISSN (Electronic)2041-3211

Bibliographical note

Publisher Copyright:
© The Royal Society of Chemistry 2017.

ASJC Scopus subject areas

  • Drug Discovery


Dive into the research topics of 'Emerging Targets in Anti-Tubercular Drug Design'. Together they form a unique fingerprint.

Cite this